Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | IDH1 | O75874 | 3/20 | 0.35 |
| ▸ | IDH2 | P48735 | 3/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.31 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.31 |
| ▸ | HTR3B | O95264 | 1/20 | 0.31 |
| ▸ | HTR3A | P46098 | 1/20 | 0.31 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.31 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.31 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22215351 | 0.90 | L3MBTL1 (0.36) | L3MBTL1IDH1IDH2CYP3A4TSHR | |
| SCHEMBL18557494 | 0.89 | L3MBTL1 (0.42) | L3MBTL1IDH1IDH2CYP3A4TSHR | |
| SCHEMBL23059309 | 0.86 | L3MBTL1 (0.36) | L3MBTL1IDH1IDH2CYP3A4TSHR | |
| SCHEMBL19727223 | 0.80 | HTT (0.40) | L3MBTL1 | |
| SCHEMBL18855225 | 0.80 | L3MBTL1 (0.39) | L3MBTL1IDH1IDH2CYP3A4TSHR | |
| SCHEMBL21948607 | 0.79 | KCNH2 (0.41) | L3MBTL1ALOX5 | |
| SCHEMBL9993771 | 0.79 | L3MBTL1 (0.38) | L3MBTL1IDH1IDH2CYP3A4TSHR | |
| SCHEMBL18855166 | 0.79 | MCHR1 (0.40) | IDH1MCHR1 | |
| SCHEMBL18672329 | 0.78 | KCNH2 (0.40) | L3MBTL1ALOX5 | |
| SCHEMBL24120057 | 0.77 | L3MBTL1 (0.37) | L3MBTL1IDH1IDH2CYP3A4TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210244736-A1 | Methods for Treating Cancer Using Pyrimidine and Pyridine Compounds with BTK Inhibitory Activity | MERCK PATENT GMBH (DE) | 2021-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210244736-A1 | Methods for Treating Cancer Using Pyrimidine and Pyridine Compounds with BTK Inhibitory Activity | BTK, SYK, LCK | L3MBTL1 1963/4885IDH1 1297/4885IDH2 1310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.